Estimation of revenue potential

The term of commercial product creation - anticoagulant drug, oral form of factor Xa inhibitor on indications of use for prophylaxis of thromboembolism after knee or hip replacement surgeries- 2020. The use on indications for prophylaxis and prevention of thromboembolism in atrial fibrillation - 2021, which is associated with the need to collect a broad evidence base for comparison with solutions existing on the market. The cost of withdrawal at the stage of the completed 2nd phase of CT at the end of 2018 is USD 30-50 million. (under the terms of a similar deal between Merck and Portola for the purchase of Betrixaban Merck, it was agreed to pay Portola USD 50 million as an initial payment. Portola was entitled to additional remuneration of USD 420 million, subject to the successful passage of certain stages. Portola also had the right to receive double-digit deductions from all sales).

Expected revenue:

TOTAL during the patent validity: RUB 15,731 mln